BIIB Biogen Inc.

+0.11  (0%)
Previous Close 344.47
Open 346.56
Price To book 6.29
Market Cap 72855151037
Shares 211,431,746
Volume 1,244,497
Short Ratio 2.43
Av. Daily Volume 1,228,121

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 initiated April 2017.
BMS-986168 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 2 planned.
BMS-986168 - Anti Tau
Alzheimer’s disease
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 to be initiated in 2018.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b to be initiated 4Q 2017.
Opicinumab (anti-LINGO)
Multiple sclerosis (MS)
Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b enrollment to be completed 2017.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 initiated 2016. Data due in 2018.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Phase 2 ongoing.
Dapirolizumab pegol (anti-CD40L)
Phase 2 dosing commenced October 2016.
BIIB059 (anti-BDCA2)
Phase 2 data due by the end of 2017.
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2 to be completed 2017.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data released June 8, 2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)

Latest News

  1. Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
  2. See what the IHS Markit Score report has to say about Biogen Inc.
  3. Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
  4. Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
  5. Biogen’s stock gets a big boost from 2 upgrades a week before earnings
  6. Biogen Could Rise 20% on Healthy Outlook
  7. Where to Find Value in Healthcare Stocks
  8. Two positive calls on this biotech name
  9. Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments
  10. Should You Expect Biogen Inc (BIIB) To Continue Delivering An ROE Of 28.62%?
  11. 3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
  12. [$$] More Biotechs That Can Beat Q3 Views
  13. 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
  14. It's Friday the 13th, and these are 4 freaky good stocks ...
  15. This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due
  16. Can Biotech Stay Healthy Through the End of 2017?
  17. Celgene, Biogen Are Poised to Break Out: A Technical View
  18. Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
  19. 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
  20. Better Buy: Biogen Inc. vs. Celgene